California Governor Gavin Newsom has stepped directly into one of the biggest healthcare debates of the decade: the soaring cost and growing demand for GLP-1 medications like Ozempic, Wegovy, and Zepbound. These drugs—once niche treatments for type 2 diabetes—are now blockbusters due to their effectiveness for weight management. Their high price tags, however, have put pressure on state budgets, insurance systems, and families trying to access them.
While Newsom hasn’t cut the retail price of GLP-1s themselves, his administration has made significant policy moves that will reshape how, when, and whether Californians can access these medications—especially those relying on the state’s safety-net insurance program.
This is what patients, caregivers, and anyone relying on GLP-1 medications needs to know.
California Ends Medi-Cal Coverage for GLP-1s Used Only for Weight Loss
Beginning January 1, 2026, Medi-Cal will no longer cover GLP-1 medications prescribed strictly for weight loss. That means drugs like Wegovy, Zepbound, and other weight-loss-specific GLP-1s will become fully out-of-pocket for the state’s low-income enrollees unless they are prescribed for another FDA-approved medical indication.
However, Medi-Cal will continue covering semaglutide and tirzepatide when used to treat type 2 diabetes. Medical necessity rules still apply, but those using GLP-1 drugs for diabetes are not affected by the weight-loss exclusion.
Why is this happening?
Two reasons:
- Budget pressure. GLP-1 medications can cost $1,000+ per month. With more Californians seeking prescriptions, state spending skyrocketed.
- Long-term cost concerns. Policymakers argue the long-term budget impact is unsustainable if weight-loss coverage continues unchecked.
Critics warn the move may increase rates of obesity-related illness, potentially raising long-term healthcare spending. Supporters say the shift protects essential programs during a historic deficit.
Newsom’s Larger Plan: Cutting Drug Costs by Targeting PBMs
Even without lowering GLP-1 retail prices, Newsom has aggressively pursued prescription-drug cost reform in California.
One of his most consequential moves came in 2025 with the signing of Senate Bill 41 (SB 41). This law takes aim at pharmacy benefit managers (PBMs)—the middlemen who negotiate drug prices but often profit from complex, opaque pricing practices.
SB 41 does three major things:
- Requires PBMs to pass through all manufacturer rebates to health plans.
- Bans spread pricing, a practice that inflates drug costs.
- Brings PBMs under stricter state regulatory oversight.
These reforms are designed to make prescription drugs more transparent and reduce total system costs for consumers—including, eventually, those using GLP-1 medications.
Can GLP-1 Prices Themselves Come Down? California Thinks So.
Newsom’s CalRx initiative—California’s state-branded prescription drug program—proved the state can reduce prices on essential medications, at least in some categories.
In late 2025, California announced its CalRx insulin glargine would sell for just $55 for a pack of five pens, dramatically below typical retail pricing. That win raised questions about whether GLP-1s could someday get similar treatment.
Right now, there is no CalRx version of semaglutide or tirzepatide. But Newsom’s team has not ruled out pursuing a state-backed competitor or negotiating bulk-purchase discounts with manufacturers.
The message is clear: California wants a seat at the table when it comes to drug pricing—GLP-1s included.
What This Means for Patients in 2025–2026
Here’s what California residents need to take away from the Newsom administration’s moves:
1. Retail GLP-1 prices have not been lowered.
The list price for drugs like Wegovy and Ozempic remains unchanged.
2. Access is becoming more limited under Medi-Cal.
If you use a GLP-1 for weight loss only, coverage ends January 2026.
3. Diabetes patients remain protected.
Medi-Cal will still cover GLP-1 drugs when prescribed to manage type 2 diabetes.
4. Structural reforms may bring prices down later.
California’s PBM reforms and CalRx strategy are meant to reduce overall drug costs by increasing transparency and competition.
5. Political polarization is fueling the conversation.
Because Newsom is a high-profile national figure, every move he makes—including drug-pricing policy—tends to spark debate far beyond California.
The Bottom Line
Governor Gavin Newsom hasn’t directly slashed the price of GLP-1 medications, but he has reshaped how Californians access them and taken aggressive steps to combat prescription drug inflation. By tightening Medi-Cal eligibility for weight-loss GLP-1s and overhauling the PBM landscape, California is betting big that structural reform—not one-off discounts—is the path toward long-term affordability.
As GLP-1 demand grows nationwide, California’s approach may become a model—or a cautionary tale—for other states wrestling with the same cost pressures.
Top Weight Loss Programs
Remedy Meds
Medvi
Hims
ShedRX
